Source: International Congress 2015 – Interstitial lung diseases II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vanessa Maria Ferreira dos Santos (Ovar, Portugal), Vanessa Santos, Eva Padrão, Inês Neves, Natália Melo, Patrícia Mota, Rui Cunha, José Pereira, António Morais. Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification?. Eur Respir J 2015; 46: Suppl. 59, 3844

Member's Comments

No comment yet.

Related content which might interest you: Mortality and survival predictor in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Sarcoidosis Year: 2016 Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Familial pulmonary fibrosis: Clinical-functional and radiological features Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Emphysematous changes in chronic hypersensitivity pneumonitis: A retrospective analysis of 12 patients Source: International Congress 2016 – Orphan diseases II Year: 2016 Variation in mortality from interstitial lung disease by diagnosis Source: International Congress 2015 – IIPs: orphan Year: 2015 Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Chronic interstitial lung disease in children: diagnosis and treatment Source: International Congress 2016 – PG6 Lung fibrosis and sarcoidosis Year: 2016 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Primary pulmonary interstitial glycogenosis. Long term outcome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Interstitial lung disease caused by designer drugs Source: International Congress 2015 – A morphological view of chest pathology Year: 2015 Usual interstitial pneumonia preceding rheumatoid arthritis: Clinical, imaging, and histopathologic features Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Can current guidelines improve the diagnosis of a usual interstitial pneumonia among general radiologists? Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015